PF 05206388

Drug Profile

PF 05206388

Alternative Names: Human embryonic stem cell derived retinal pigment epithelium - Pfizer; PF-05206388; PF-5206388

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer; University College London
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Age-related macular degeneration

Most Recent Events

  • 29 Mar 2017 Pfizer initiateslong term safey follow-up study for Age-related macular degeneration in United Kingdom (NCT03102138)
  • 04 Jan 2017 Pfizer suspends participant enrolment in the phase I trial in Age-related macular degeneration in United Kingdom (NCT01691261)
  • 01 Jun 2015 Phase-I clinical trials in Age-related macular degeneration (In the elderly) in United Kingdom (Intraocular; Implant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top